Targeted radionuclide therapies for pancreatic cancer

M. Shah, R. Da Silva, Claudia Gravekamp, S. K. Libutti, Tony Abraham, E. Dadachova

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Pancreatic malignancies, the fourth leading cause of cancer deaths, have an aggressive behavior with poor prognosis, resulting in a 5-year survival rate of only 4%. It is typically a silent malignancy until patients develop metastatic disease. Targeted radionuclide therapies of cancer such as radiolabeled peptides, which bind to the receptors overexpressed by cancer cells and radiolabeled antibodies to tumor-specific antigens provide a viable alternative to chemotherapy and external beam radiation of metastatic cancers. Multiple clinical trials of targeted radionuclide therapy of pancreatic cancer have been performed in the last decade and demonstrated safety and potential efficacy of radionuclide therapy for treatment of this formidable disease. Although a lot of progress has been made in treatment of pancreatic neuroendocrine tumors with radiolabeled 90 Y and 177 Lu somatostatin peptide analogs, pancreatic adenocarcinomas remain a major challenge. Novel approaches such as peptides and antibodies radiolabeled with alpha emitters, pre-targeting, bispecific antibodies and biological therapy based on the radioactive tumorlytic bacteria might offer a potential breakthrough in treatment of pancreatic adenocarcinomas.

Original languageEnglish (US)
Pages (from-to)375-379
Number of pages5
JournalCancer Gene Therapy
Volume22
Issue number8
DOIs
StatePublished - Aug 18 2015

Fingerprint

Pancreatic Neoplasms
Radioisotopes
Neoplasms
Peptides
Adenocarcinoma
Therapeutics
Bispecific Antibodies
Biological Therapy
Neuroendocrine Tumors
Antibodies
Neoplasm Antigens
Somatostatin
Cause of Death
Survival Rate
Clinical Trials
Radiation
Bacteria
Safety
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Medicine
  • Molecular Biology

Cite this

Targeted radionuclide therapies for pancreatic cancer. / Shah, M.; Da Silva, R.; Gravekamp, Claudia; Libutti, S. K.; Abraham, Tony; Dadachova, E.

In: Cancer Gene Therapy, Vol. 22, No. 8, 18.08.2015, p. 375-379.

Research output: Contribution to journalArticle

Shah, M, Da Silva, R, Gravekamp, C, Libutti, SK, Abraham, T & Dadachova, E 2015, 'Targeted radionuclide therapies for pancreatic cancer', Cancer Gene Therapy, vol. 22, no. 8, pp. 375-379. https://doi.org/10.1038/cgt.2015.32
Shah, M. ; Da Silva, R. ; Gravekamp, Claudia ; Libutti, S. K. ; Abraham, Tony ; Dadachova, E. / Targeted radionuclide therapies for pancreatic cancer. In: Cancer Gene Therapy. 2015 ; Vol. 22, No. 8. pp. 375-379.
@article{3c8541f80f1642708e6724ab6b2f38c6,
title = "Targeted radionuclide therapies for pancreatic cancer",
abstract = "Pancreatic malignancies, the fourth leading cause of cancer deaths, have an aggressive behavior with poor prognosis, resulting in a 5-year survival rate of only 4{\%}. It is typically a silent malignancy until patients develop metastatic disease. Targeted radionuclide therapies of cancer such as radiolabeled peptides, which bind to the receptors overexpressed by cancer cells and radiolabeled antibodies to tumor-specific antigens provide a viable alternative to chemotherapy and external beam radiation of metastatic cancers. Multiple clinical trials of targeted radionuclide therapy of pancreatic cancer have been performed in the last decade and demonstrated safety and potential efficacy of radionuclide therapy for treatment of this formidable disease. Although a lot of progress has been made in treatment of pancreatic neuroendocrine tumors with radiolabeled 90 Y and 177 Lu somatostatin peptide analogs, pancreatic adenocarcinomas remain a major challenge. Novel approaches such as peptides and antibodies radiolabeled with alpha emitters, pre-targeting, bispecific antibodies and biological therapy based on the radioactive tumorlytic bacteria might offer a potential breakthrough in treatment of pancreatic adenocarcinomas.",
author = "M. Shah and {Da Silva}, R. and Claudia Gravekamp and Libutti, {S. K.} and Tony Abraham and E. Dadachova",
year = "2015",
month = "8",
day = "18",
doi = "10.1038/cgt.2015.32",
language = "English (US)",
volume = "22",
pages = "375--379",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Targeted radionuclide therapies for pancreatic cancer

AU - Shah, M.

AU - Da Silva, R.

AU - Gravekamp, Claudia

AU - Libutti, S. K.

AU - Abraham, Tony

AU - Dadachova, E.

PY - 2015/8/18

Y1 - 2015/8/18

N2 - Pancreatic malignancies, the fourth leading cause of cancer deaths, have an aggressive behavior with poor prognosis, resulting in a 5-year survival rate of only 4%. It is typically a silent malignancy until patients develop metastatic disease. Targeted radionuclide therapies of cancer such as radiolabeled peptides, which bind to the receptors overexpressed by cancer cells and radiolabeled antibodies to tumor-specific antigens provide a viable alternative to chemotherapy and external beam radiation of metastatic cancers. Multiple clinical trials of targeted radionuclide therapy of pancreatic cancer have been performed in the last decade and demonstrated safety and potential efficacy of radionuclide therapy for treatment of this formidable disease. Although a lot of progress has been made in treatment of pancreatic neuroendocrine tumors with radiolabeled 90 Y and 177 Lu somatostatin peptide analogs, pancreatic adenocarcinomas remain a major challenge. Novel approaches such as peptides and antibodies radiolabeled with alpha emitters, pre-targeting, bispecific antibodies and biological therapy based on the radioactive tumorlytic bacteria might offer a potential breakthrough in treatment of pancreatic adenocarcinomas.

AB - Pancreatic malignancies, the fourth leading cause of cancer deaths, have an aggressive behavior with poor prognosis, resulting in a 5-year survival rate of only 4%. It is typically a silent malignancy until patients develop metastatic disease. Targeted radionuclide therapies of cancer such as radiolabeled peptides, which bind to the receptors overexpressed by cancer cells and radiolabeled antibodies to tumor-specific antigens provide a viable alternative to chemotherapy and external beam radiation of metastatic cancers. Multiple clinical trials of targeted radionuclide therapy of pancreatic cancer have been performed in the last decade and demonstrated safety and potential efficacy of radionuclide therapy for treatment of this formidable disease. Although a lot of progress has been made in treatment of pancreatic neuroendocrine tumors with radiolabeled 90 Y and 177 Lu somatostatin peptide analogs, pancreatic adenocarcinomas remain a major challenge. Novel approaches such as peptides and antibodies radiolabeled with alpha emitters, pre-targeting, bispecific antibodies and biological therapy based on the radioactive tumorlytic bacteria might offer a potential breakthrough in treatment of pancreatic adenocarcinomas.

UR - http://www.scopus.com/inward/record.url?scp=84939464135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939464135&partnerID=8YFLogxK

U2 - 10.1038/cgt.2015.32

DO - 10.1038/cgt.2015.32

M3 - Article

C2 - 26227823

AN - SCOPUS:84939464135

VL - 22

SP - 375

EP - 379

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 8

ER -